Disease · MONDO_0006640

adrenal gland hyperfunction

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. adrenal gland hyperfunction. Diseases, record MONDO_0006640. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006640

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: adrenal gland hyperfunction; Open Targets
Open Targets ID: MONDO_0006640; Open Targets
Other names: Adrenocortical Hyperfunction, Overproduction of cortisol, disorder of corticoadrenal overactivity, hyperadrenalism, hypercortisolemia, hypercortisolism, hypercortisolism (disorder); Open Targets
Disease Ontology: DOID:3947; Disease Ontology
MeSH: D000308; MeSH
Highest stage of its drugs: Approval, for 2 of its 5 drugs, from DailyMed; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LEVOKETOCONAZOLE	CHEMBL295698	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
RELACORILANT	CHEMBL4068611	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOFUTRIBEN	CHEMBL5314513	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METYRAPONE	CHEMBL934	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CYP11B1	Cytochrome P450 11B1, mitochondrial	2	Cytochrome P450 11B1 inhibitor; Cytochrome P450 11B1, mitochondrial inhibitor	Approval	https://conductscience.org/library/genes/1584	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
CYP11A1	Cholesterol side-chain cleavage enzyme, mitochondrial	1	Cytochrome P450 11A1 inhibitor	Approval	https://conductscience.org/library/genes/1583	Drugs and targets
CYP11B2	Cytochrome P450 11B2, mitochondrial	1	Cytochrome P450 11B2 inhibitor	Approval	https://conductscience.org/library/genes/1585	Drugs and targets
CYP17A1	Steroid 17-alpha-hydroxylase/17,20 lyase	1	Cytochrome P450 17A1 inhibitor	Approval	https://conductscience.org/library/genes/1586	Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04308590	A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas	Phase 3	137	2025-08-03	Hypercortisolism	RELACORILANT	Its record names the disease	ClinicalTrials.gov
NCT05436639	SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Phase 2	30		Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic	CLOFUTRIBEN	Its record names the disease	ClinicalTrials.gov
NCT05255900	Effects of Metyrapone in Patients With Hypercortisolism		20		Hypercortisolism	METYRAPONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Relacorilant vs Placebo: Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.	67 of 68	60 of 69	137	NCT04308590	Trial comparisons
Relacorilant vs Placebo: deaths from any cause	1 of 68	0 of 69	137	NCT04308590	Trial comparisons
Relacorilant vs Placebo: serious adverse events	15 of 68	4 of 69	137	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg	10 of 42	13 of 42	84	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)	9 of 42	13 of 42	84	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With Any Dose Decrease in Antihypertensive Medication	7 of 22	5 of 33	55	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL	1 of 27	0 of 28	55	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication	1 of 22	5 of 33	55	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With Any Dose Decrease in Diabetes Medication	0 of 15	0 of 25	40	NCT04308590	Trial comparisons
Relacorilant vs Placebo: Number of Patients With Any Dose Increase or Switch in Diabetes Medication	4 of 15	3 of 25	40	NCT04308590	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006640

GET https://conductscience.org/api/diseases/v1/MONDO_0006640/drugs

API reference For AI assistants